Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark R. Bamforth
AddedMar 31, 2024
UpdatedJun 28, 2026
Mark R. Bamforth

Mark R. Bamforth

Board Member, Continuus Pharmaceuticals

CrunchbaseLinkedIn

Mark R. Bamforth's Career

Continuus Pharmaceuticals
Continuus Pharmaceuticals

Woburn, MA, US

Board Member· Board
Arranta Bio
Arranta Bio

Watertown, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark R. Bamforth's Career

Continuus Pharmaceuticals
Continuus Pharmaceuticals
Series B$9.1M492012Woburn, MA, US
Board Member· Board

Leadership at Continuus Pharmaceuticals

Jonathan FlemingJonathan FlemingBoard Member
Bayan TakizawaBayan TakizawaCo-Founder
Salvatore MasciaSalvatore MasciaCo-Founder

Similar to Continuus Pharmaceuticals

Continuity PharmaContinuity PharmaWest Lafayette, IN, USManufacturing Systemsest. 2018Continuity PharmaWest Lafayette, IN, US · est. 2018

Continuity Pharma: Modern, efficient systems for manufacturing essential generic medicines.

Seed · $1.5M9
Selkirk PharmaSelkirk PharmaSpokane, WA, USPharmaceuticalsest. 2018Selkirk PharmaSpokane, WA, US · est. 2018

Selkirk Pharma: A leading Contract Manufacturing Organization for the pharmaceutical industry.

Series B · $82.1M64
Societal CdmoSocietal CdmoExton, PA, USPharmaceuticalsest. 1982Societal CdmoExton, PA, US · est. 1982

Societal CDMO, a leading bi-coastal medical organization, offers comprehensive pharmaceutical development, manufacturing, and logistics services globally.

Public275
Pharmaceutics InternationalPharmaceutics InternationalHunt Valley, MD, USDrug Developmentest. 2016Pharmaceutics InternationalHunt Valley, MD, US · est. 2016

Founded in 1994, Pharmaceutics International, Inc. is a contract development and manufacturing firm specializing in biological research.

Private Equity · $148M375
Arranta Bio
Arranta Bio
Series B$82M1022019Watertown, MA, US
Board Member· Board

Leadership at Arranta Bio

Iain BairdIain BairdBoard Member

Similar to Arranta Bio

Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
BioPlxBioPlxBoulder, CO, USBiotherapeuticsest. 2015BioPlxBoulder, CO, US · est. 2015

BioPlx, an advanced microbiome company, develops non-antibiotic solutions to control infectious diseases using live bio-therapeutic products.

Pre-Seed · $2.7M30
Arrivo BioVenturesArrivo BioVenturesMorrisville, NC, USClinical Drugsest. 2015Arrivo BioVenturesMorrisville, NC, US · est. 2015

Arrivo BioVentures LLC, a US-based biopharmaceutical company, develops and manufactures clinical drugs.

Series B · $94.3M12
AvantBioAvantBioVancouver, WA, USBiomedicine, Reagentsest. 2008AvantBioVancouver, WA, US · est. 2008

AvantBio: Innovating in bioscience and biomedicine for therapeutic and research markets.

Angel · $300k4

Mark R. Bamforth's Co-Investors

Philip ReillyPhilip ReillyCo-invested · Thymmune Therapeutics SeedGeorge ChurchGeorge ChurchCo-invested · Thymmune Therapeutics SeedJohn MaraganoreJohn MaraganoreCo-invested · Thymmune Therapeutics SeedJudy PagliucaJudy PagliucaCo-invested · Thymmune Therapeutics SeedJames FordyceJames FordyceCo-invested · Thymmune Therapeutics Seed

Mark R. Bamforth's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Mark R. Bamforth

Deborah ZanforlinDeborah ZanforlinCo-Founder · ConquerXDavid ThompsonDavid ThompsonCo-Founder · 64x BioIan MarkramIan MarkramBoard Member · InvestorEnrique NavasEnrique NavasFounder · Q BioMedVijay PandeVijay PandeBoard Member · SchrödingerSYLVAIN DURANDSYLVAIN DURANDFounder · Bioimpact